Seeking Alpha

More on AbbVie (ABBV -0.8%) guidance: expects 2013 sales of above $18B vs consensus of $18.2B...

More on AbbVie (ABBV -0.8%) guidance: expects 2013 sales of above $18B vs consensus of $18.2B and $18.1B last year; forecasts Q1 adjusted EPS of $0.64-$0.66 vs $0.69. Predicts low double-digit Humira growth vs 17% last year, although Abbot was known for conservative projections. AbbVie sees additional $1B in revenue over next 5 years from emerging markets; interested in small "tuck in" acquisitions. Forecasts that new drugs will drive growth from H2 2015.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|